药物对比
Bexagliflozin vs Troglitazone
Bexagliflozin 与 Troglitazone：SGLT2抑制剂 vs 已撤市TZD，用于治疗2型糖尿病。Troglitazone 曾导致致死性肝损伤，现已不再使用。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when patients or providers examine discontinued diabetes drugs versus modern SGLT2 inhibitors like Bexagliflozin.
结论
Bexagliflozin is preferred over Troglitazone because the latter was withdrawn for serious liver risks and is not available.
全部药物对比